Want to see CVKD full AI Analyst Report?
CVKD Stock Chart & Stats
$2.04
-$0.06(-2.94%)
At close: 4:00 PM EDT
$2.04
-$0.06(-2.94%)
Day’s Range― - ―
52-Week Range$1.54 - $14.64
Previous CloseN/A
Volume28.12K
Average Volume (3M)57.36K
Market Cap
$5.74M
Enterprise Value$7.34
Total Cash (Recent Filing)$2.39M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Nov 05, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.90
Shares Outstanding3,567,592
10 Day Avg. Volume57,981
30 Day Avg. Volume57,363
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)4.94
Price to Sales (P/S)0.00
P/FCF Ratio-1.07
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$29.00Price Target Upside1321.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-5.25
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt reduces interest burden and financial distress risk, giving Cadrenal greater flexibility to fund clinical development. However, this advantage supports resilience rather than eliminating the need for future equity or partnership financing.
Financing Extends RunwayThe financing provides capital to continue CAD-1005 and tecarfarin development and supports partnering efforts. Extending cash runway into 2027 may reduce immediate execution pressure, although future proceeds depend on warrant exercise.
Partnering-Focused Pipeline StrategyA partnership-driven model could provide external development capital, regulatory expertise and broader commercialization reach. The portfolio spans acute, chronic and rare cardiovascular needs, potentially improving strategic attractiveness to larger pharmaceutical companies.
Bears Say
Pre-Revenue BusinessWithout product revenue, Cadrenal has no operating sales base to offset research, clinical and corporate costs. The company must create value through successful development, approvals and partnerships before it can demonstrate commercial operating leverage.
Persistent Losses And Cash BurnSustained negative cash generation means continued external funding is required to advance programs. Rising spending and widening losses increase dilution and execution risk, particularly if clinical milestones take longer or partnerships do not materialize.
Executive Transition RiskReplacing the chief medical officer can disrupt clinical oversight, regulatory interactions and development prioritization. The transition occurs while multiple programs are advancing, so maintaining continuity and recruiting experienced leadership are important execution requirements.
Cadrenal Therapeutics, Inc. News
CVKD FAQ
What was Cadrenal Therapeutics, Inc.’s price range in the past 12 months?
Cadrenal Therapeutics, Inc. lowest stock price was $1.54 and its highest was $14.64 in the past 12 months.
What is Cadrenal Therapeutics, Inc.’s market cap?
Cadrenal Therapeutics, Inc.’s market cap is $5.74M.
When is Cadrenal Therapeutics, Inc.’s upcoming earnings report date?
Cadrenal Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 72 days.
How were Cadrenal Therapeutics, Inc.’s earnings last quarter?
Cadrenal Therapeutics, Inc. released its earnings results on Aug 13, 2026. The company reported -$1.14 earnings per share for the quarter, beating the consensus estimate of -$1.42 by $0.28.
Is Cadrenal Therapeutics, Inc. overvalued?
According to Wall Street analysts Cadrenal Therapeutics, Inc.’s price is currently Undervalued.
Does Cadrenal Therapeutics, Inc. pay dividends?
Cadrenal Therapeutics, Inc. does not currently pay dividends.
What is Cadrenal Therapeutics, Inc.’s EPS estimate?
Cadrenal Therapeutics, Inc.’s EPS estimate is -1.
How many shares outstanding does Cadrenal Therapeutics, Inc. have?
Cadrenal Therapeutics, Inc. has 3,567,592 shares outstanding.
What happened to Cadrenal Therapeutics, Inc.’s price movement after its last earnings report?
Cadrenal Therapeutics, Inc. reported an EPS of -$1.14 in its last earnings report, beating expectations of -$1.42. Following the earnings report the stock price went up 0.538%.
Which hedge fund is a major shareholder of Cadrenal Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CVKD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
CVKD Stock 12 Month Forecast
Average Price Target
$29.00
▲(1321.57% Upside)
Technical Analysis
Daré Bioscience
―
Vyome Holdings
―
Collplant Holdings
―
Lunai Bioworks
―
Tao Synergies
―
Ownership Overview
8.37% Insiders
1.65% Mutual Funds
0.04% Other Institutional Investors
88.51% Public Companies and
Individual Investors